Other Events ·
AstraZeneca announced positive Phase III results from the CLARITY-Gastric01 trial for sonesitatug vedotin (Sone-Ve)…
AZNCFAstrazeneca PLC
AstraZeneca announced positive Phase III results from the CLARITY-Gastric01 trial for sonesitatug vedotin (Sone-Ve), an antibody-drug conjugate targeting CLDN18.2. The trial met its dual primary endpoints, demonstrating a statistically significant improvement in overall survival (OS) in 3rd and later-line treatment and a key secondary endpoint of OS in the 2nd and later-line setting. Sone-Ve showed a trend toward improved progression-free survival (PFS) in the 2nd and later-line setting, though it did not reach statistical significance. These results may allow for expansion of the target population to include patients with ≥25% CLDN18.2 expression. AstraZeneca is a biopharmaceutical company that develops and commercializes prescription medicines.